WIXOM, Mich., Dec. 12, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and secondary hyperparathyroidism, today announced that the independent Data Safety Monitoring Board (DSMB) providing oversight for the Company’s Phase III SFP iron replacement therapy program met and informed the company that it has carefully reviewed the cumulative safety data from the Phase III CRUISE studies and identified no safety concerns. The DSMB also recommended the continuation of the Phase III CRUISE studies with no modifications. SFP, a key product in the company’s development pipeline, is in Phase III multi-center clinical trials for use as an iron replacement therapeutic in ESRD patients.
